EMA to Hold its Second Public Meeting on COVID-19 Vaccines
The agency is organizing a second public meeting on January 8, 2021 to discuss the assessment, approval, and roll-out of new COVID-19 vaccines.
The European Medicines Agency (EMA) is organizing a second public meeting regarding the assessment, approval, and roll-out of new COVID-19 vaccines. At the meeting, EMA will discuss plans to ensure the safety of COVID-19 vaccines and the roles that the European Commission and the national public health authorities will play in the roll-out of the vaccines, according to a press release dated Dec. 22, 2020.
The meeting will be held online on January 8 and will be attended by EMA executive director Emer Cooke and members of EMA’s human medicines and safety committees, among others. An online form is being made available for those who wish to submit questions to panelists at the meeting. The agency has requested that these questions be submitted by Dec. 31, 2020.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
